Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer to Use ActivX Technology in Drug Discovery, Proteomic Profiling

NEW YORK, Feb. 9 (GenomeWeb News) - Pfizer researchers will use ActivX's high-throughput protein analysis in drug discovery, proteomic profiling, compound selectivity, and other projects, ActivX said today.


ActivX Biosciences, a subsidiary of Tokyo-based Kyorin Pharmaceuticals, also said that it and the drug giant will collaborate on multiple future projects.


Financial details of the agreement, which is part of an expanding partnership between the two companies, included an upfront technology access fee, along with research support payments by Pfizer.


As GenomeWeb News reported earlier this month, ActivX was acquired by Kyorin Pharameceuticals. The company paid $21 million for the proteomics shop which it wholly owns and plans to use as its USdrug-discovery and development center.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.